American Journal of Epidemiology Vol. 130, No. 2: 221-228
Copyright © 1989 by The Johns Hopkins University School of Hygiene and Public Health
research-article |
PROGNOSIS AFTER BREAST CANCER DIAGNOSIS IN WOMEN EXPOSED TO ESTROGEN AND ESTROGEN-PROGESTOGEN REPLACEMENT THERAPY
1Department of Surgery, University Hospital Uppsala, Sweden
2Department of Gynecology and Obstetrics, University Hospital Uppsala, Sweden
3Department of Statistics, University of Uppsala Uppsala, Sweden
4Data Center, University of Uppsala Uppsala, Sweden
Reprint requests to Dr. Hans-Olov Adami, Department of Surgery, University Hospital, S-751 85 Uppsala, Sweden
The association between survival in breast cancer and menopausal hormone treatment prior to diagnosis was analyzed by comparing 261 women who developed the disease in a population-based cohort of estrogen-treated women with 6,617 breast cancer patients without any recorded estrogen treatment drawn from the same population. Complete follow-up was achieved during the 0–9 years of observation. The relative survival rate was significantly higher (p = 0.02), by about 10 percentage points at eight years, in patients who had received estrogen treatment—corresponding to an approximately 40% reduction in excess mortality. The more favorable course could be confirmed only in patients aged 50 years or more at diagnosis (p < 0.01) and was most pronounced in recent users, that is, in women whose treatment was ongoing (p < 0.01) or had been discontinued within one year prior to diagnosis. The time from first use to diagnosis and the total duration of estrogen medication were virtually unrelated to survival when the effect of recency was taken into account in multivariate analyses. The authors were unable to examine the effect of stage at diagnosis on the results. Several factors, particularly selection bias and surveillance bias, might have affected the results in favor of the women receiving hormone replacement therapy, but there is a possibility that exogenous female sex hormones affect survival in women with breast cancer.
breast neoplasma; estrogens; prognosis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. A. Newcomb, K. M. Egan, A. Trentham-Dietz, L. Titus-Ernstoff, J. A. Baron, J. M. Hampton, M. J. Stampfer, and W. C. Willett Prediagnostic Use of Hormone Therapy and Mortality After Breast Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 864 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Armstrong, J. S. Schwartz, T. Randall, S. C. Rubin, and B. Weber Hormone Replacement Therapy and Life Expectancy After Prophylactic Oophorectomy in Women With BRCA1/2 Mutations: A Decision Analysis J. Clin. Oncol., March 15, 2004; 22(6): 1045 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Antoine, F. Liebens, B. Carly, A. Pastijn, and S. Rozenberg Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial Hum. Reprod., March 1, 2004; 19(3): 741 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Osborne, V. Bardou, T. A. Hopp, G. C. Chamness, S. G. Hilsenbeck, S. A. W. Fuqua, J. Wong, D. C. Allred, G. M. Clark, and R. Schiff Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer J Natl Cancer Inst, March 5, 2003; 95(5): 353 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan, S. Gapstur, and M. Morrow Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart Disease J Natl Cancer Inst, October 3, 2001; 93(19): 1449 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Dopp and J. M Kolesar Risk of breast cancer associated with hormone replacement therapy Journal of Oncology Pharmacy Practice, September 1, 1999; 5(3): 109 - 116. [Abstract] [PDF]
|
|
|
|
 |
|
 S. M. Gapstur, M. Morrow, and T. A. Sellers Hormone Replacement Therapy and Risk of Breast Cancer With a Favorable Histology: Results of the Iowa Women's Health Study JAMA, June 9, 1999; 281(22): 2091 - 2097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Fowble, A. Hanlon, G. Freedman, A. Patchefsky, H. Kessler, N. Nicolaou, J. Hoffman, E. Sigurdson, M. Boraas, and L. Goldstein Postmenopausal Hormone Replacement Therapy: Effect on Diagnosis and Outcome in Early-Stage Invasive Breast Cancer Treated With Conservative Surgery and Radiation J. Clin. Oncol., June 1, 1999; 17(6): 1680 - 1680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Santen and G. R. Petroni Relative Versus Attributable Risk of Breast Cancer from Estrogen Replacement Therapy J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1875 - 1881. [Full Text]
|
|
|
|
|
|
R. Vassilopoulou-Sellin, L. Asmar, G. N. Hortobagyi, M. J. Klein, M. McNeese, S. E. Singletary, and R. L. Theriault Estrogen Replacement Therapy After Localized Breast Cancer: Clinical Outcome of 319 Women Followed Prospectively J. Clin. Oncol., May 1, 1999; 17(5): 1482 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Schairer, M. Gail, C. Byrne, P. S. Rosenberg, S. R. Sturgeon, L. A. Brinton, and R. N. Hoover Estrogen Replacement Therapy and Breast Cancer Survival in a Large Screening Study J Natl Cancer Inst, February 3, 1999; 91(3): 264 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Brinton and C. Schairer Postmenopausal Hormone-Replacement Therapy -- Time for a Reappraisal? N. Engl. J. Med., June 19, 1997; 336(25): 1821 - 1822. [Full Text]
|
|
|
|
|
|
N. F. Col, M. H. Eckman, R. H. Karas, S. G. Pauker, R. J. Goldberg, E. M. Ross, R. K. Orr, and J. B. Wong Patient-Specific Decisions About Hormone Replacement Therapy in Postmenopausal Women JAMA, April 9, 1997; 277(14): 1140 - 1147. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Harding, W F Knox, E B Faragher, A Baildam, and N J Bundred Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit BMJ, June 29, 1996; 312(7047): 1646 - 1647. [Full Text]
|
|
|
|
 |
|
 R. D. Gambrell Jr Hormone Replacement Therapy and Breast Cancer Risk Arch Fam Med, June 1, 1996; 5(6): 341 - 348. [Abstract] [PDF]
|
|
|
|
|
|
J. L. Stanford and N. S. Weiss Hormone Replacement Therapy and Breast Cancer Arch Fam Med, June 1, 1996; 5(6): 349 - 350. [Abstract] [PDF]
|
|
|
|
 |
|
 P. J. DiSai Estrogen Replacement Therapy for the Breast Cancer Survivor Reproductive Sciences, March 1, 1996; 3(2): 57 - 59. [PDF]
|
|
|
|
|
|
H.-O. Adami and I. Persson Hormone Replacement and Breast Cancer: A Remaining Controversy? JAMA, July 12, 1995; 274(2): 178 - 179. [Abstract] [PDF]
|
|
|
|
|
|
P. E. Belchetz Hormonal Treatment of Postmenopausal Women N. Engl. J. Med., April 14, 1994; 330(15): 1062 - 1071. [Full Text]
|
|
|
|
|
|
K. E. Steinberg and S. B. Thacker Estrogen Therapy and the Risk of Breast Cancer-Reply JAMA, December 8, 1993; 270(22): 2686 - 2686. [Abstract] [PDF]
|
|
|
|
|
|
J. B. Henrich The Postmenopausal Estrogen/Breast Cancer Controversy JAMA, October 14, 1992; 268(14): 1900 - 1902. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Barrett-Connor Postmenopausal Estrogen and Prevention Bias Ann Intern Med, September 15, 1991; 115(6): 455 - 456. [Abstract] [PDF]
|
|
|
|
 |
|
 B. E. Henderson, A. Paganini-Hill, and R. K. Ross Decreased Mortality in Users of Estrogen Replacement Therapy Arch Intern Med, January 1, 1991; 151(1): 75 - 78. [Abstract] [PDF]
|
|
|
|
|
|
G. A. Colditz, M. J. Stampfer, W. C. Willett, C. H. Hennekens, B. Rosner, and F. E. Speizer Prospective Study of Estrogen Replacement Therapy and Risk of Breast Cancer in Postmenopausal Women JAMA, November 28, 1990; 264(20): 2648 - 2653. [Abstract] [PDF]
|
|
|
|
|
|
H.-O. Adami, R. Bergstrom, L. Holmberg, L. Klareskog, I. Persson, and J. Ponten The Effect of Female Sex Hormones on Cancer Survival: A Register-Based Study in Patients Younger Than 20 Years at Diagnosis JAMA, April 25, 1990; 263(16): 2189 - 2193. [Abstract] [PDF]
|
|